Key result
Orobol 7-O-d-glucoside demonstrates broad-spectrum anti-human rhinovirus activity in vitro with a therapeutic index >12.
Why the study?
The anti-human rhinovirus activity of orobol 7-O-d-glucoside from Lagerstroemia speciosa L. was evaluated to explore its potential as a broad-spectrum antiviral agent.
Does orobol 7-O-d-glucoside inhibit human rhinovirus replication in Hela cells?
Does orobol 7-O-d-glucoside inhibit human rhinovirus replication in Hela cells?
Orobol 7-O-d-glucoside demonstrates broad-spectrum antiviral activity against multiple human rhinovirus species in vitro, suggesting potential as a novel antiviral agent.
AIMS: The anti-human rhinovirus (HRV) activity of orobol 7-O-d-glucoside (O7G) from Lagerstroemia speciosa L. (Lythraceae) was evaluated in Hela cells. METHODS AND RESULTS: We tested anti-HRV activity of O7G using a cytopathic effect (CPE) reduction method, which exhibited broad-spectrum anti-HRVs activity with a 50% inhibitory concentration (IC(50)) ranging from 0.58 to 8.80 microg ml(-1). The 50% cytotoxicity concentration (CC(50)) of O7G is more than 100 microg ml(-1), and the derived therapeutic indices are more than 12. Ribavirin didn't possess antiviral activity against HRV15, HRV3 and HRV5, but exhibited weak antiviral activity against HRV2 and HRV3, and showed strong anti-HRV6 and -14 activities. CONCLUSIONS: These results suggest that O7G is a novel drug class with broad spectrum antiviral activity against HRV species A (HRV1B, HRV2, HRV15 and HRV40) and species B (HRV3, HRV6 and HRV14), as well as pleconaril-resistant virus (HRV5). SIGNIFICANCE AND IMPACT OF THE STUDY: Therefore, these findings provide important information for the utilization of Q7G promising broad spectrum for human rhinovirus treatment.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2010) studied Human rhinovirus infection (in vitro). Orobol 7-O-d-glucoside (O7G) vs. Ribavirin was evaluated on Anti-HRV activity (cytopathic effect reduction). Orobol 7-O-d-glucoside exhibited broad-spectrum anti-human rhinovirus activity in Hela cells with an IC50 ranging from 0.58 to 8.80 microg/ml and a therapeutic index >12.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: